Atlas Trials

Tesaro, Inc.

33 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Tesaro, Inc.

RecordFirmDate
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C) (NCT06964165)Tesaro, Inc.2022-04-14
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (NCT03955471)Tesaro, Inc.2019-10-03
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (NCT03981796)Tesaro, Inc.2019-07-18
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer (NCT03574779)Tesaro, Inc.2018-11-15
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer (NCT05751629)Tesaro, Inc.2018-11-15
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (NCT03602859)Tesaro, Inc.2018-10-11
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer (NCT03329937)Tesaro, Inc.2018-04-12
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (NCT03359850)Tesaro, Inc.2018-02-20
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (NCT03326193)Tesaro, Inc.2017-12-12
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule (NCT03329001)Tesaro, Inc.2017-12-04
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785)Tesaro, Inc.2017-10-12
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants (NCT03308942)Tesaro, Inc.2017-09-29

Track Tesaro, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.